PTSDNCT07680517
Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms
A study testing Cognitive Processing Therapy and Eye-Movement Desensitization and Reprocessing in people with PTSD and Cognitive Performance, run by Ohio State University at 1 site in United States.
Trial summary
Our long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT and EMDR) in "real-world" military… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PTSD, Cognitive Performance
- What is being tested?
- Cognitive Processing Therapy and Eye-Movement Desensitization and Reprocessing
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2026to Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- -Treatment-seeking military personnel (i.e., any assigned or aligned JSOC personnel) who meet diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting diagnostic threshold for 3 of 4 symptom criteria who are (1) 18 years of age or older; (2) current diagnosis of PTSD or subthreshold PTSD (i.e. meeting diagnostic criteria for 3 of 4 symptom criteria, assessed using the DIAMOND); (3) current military personnel; (4) ability to speak and understand the English language; and (5) ability to complete the informed consent process
Who cannot join
- (1) substance use disorder requiring medical management; (2) imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and (3) impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Fort Bragg
Fayetteville, North Carolina, 28310
Jaryd Hiser, PhD, 6146858746, jaryd.hiser@osumc.edu
About this study
Our long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT and EMDR) in "real-world" military settings. CPT and EMDR are both empirically supported psychotherapies for PTSD. To accomplish this objective, we will enroll military personnel meeting diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting threshold levels for 3 of 4 symptom criteria).
Read the detailed description
Posttraumatic stress disorder (PTSD) is considered one of the "signature injuries" of military operations and is the most frequently diagnosed mental health condition among active-duty military personnel. PTSD is associated with a host of psychological problems (i.e., intrusions, avoidance, negative alterations in cognition/mood, and hyperarousal) and negative outcomes (i.e., occupational and marital dissatisfaction, violence, alcohol and substance abuse, and suicide).1-3 PTSD has also been correlated with poorer cognitive performance across various domains including attention, working memory, processing speed, and executive functioning.4,5 These psychological problems and cognitive impairments significantly impact military personnel's deployment readiness and overall quality of life.
Numerous randomized clinical trials support the efficacy of trauma-focused treatments like cognitive processing therapy (CPT) with multiple populations including active-duty military personnel.6-8 For this reason, CPT is one of three individual manualized trauma-focused psychotherapies that is strongly recommended for the treatment of PTSD by the VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder.9 Recent advances in PTSD treatment have shown that the effects of CPT on PTSD symptom reduction and remission are retained when the treatment is delivered in a "massed" format, which entails daily therapy sessions during a 2-3 week window instead of the traditional schedule of one session per week for multiple months.16,23 Massed CPT therefore achieves similar reductions in PTSD symptoms within a much shorter timeframe. Our team has shown, for instance, that over 70% of military personnel and veterans who received CPT in this format no longer met criteria for a PTSD diagnosis at treatment end.10,11 As compared to conventional therapy delivered weekly, massed trauma therapy has higher treatment retention and treatment completion.12 Massed models are also believed to reduce distraction, avoidance, and de-motivation that typically occurs between weekly sessions.13 Meeting with a therapist daily may also increase commitment to therapy due to a greater sense of support.14 Therefore, this strategy would allow increased access to therapy due to higher patient throughput, while providing patients with rapid and sustained symptom reduction, through improved treatment engagement and improved long-term outcomes.
Despite massed CPT's considerable promise, the effectiveness of this delivery model in real-world military settings remains poorly understood because previous research has only been conducted in highly controlled settings using specially trained research therapists who are closely monitored for protocol fidelity and reduced caseloads. The effectiveness of massed CPT when implemented in real-world military settings when delivered by military behavioral health professionals working in busy clinics with high caseloads, multiple competing work demands, and limited time to pursue case consultation and clinical supervision remains unknown, limiting our understanding of how previous research findings will translate to practice settings within a busy military operational environment. These possible barriers to effective implementation are magnified in Special Operations Forces (SOF) units, which typically have a greater number of deployments and often experience more intense combat than conventional forces-two factors associated with higher prevalence of PTSD.15,16 This is especially true for active-duty military personnel, who show attenuated treatment response as compared to civilians.17,18 Recent research has suggested that over 50% of service members retain their PTSD diagnosis after completing weekly CPT.7 PTSD symptom persistence may be explained by insufficient engagement of key causal factors: first, CPT may not induce enough change in relevant causal factors for recovery to occur, implicating the need for higher "doses" of therapy; second, CPT may induce change in only some, but not enough, causal factors, implicating the need for multiple (or different) treatments that target a broader range of causal factors. Supporting the first possibility is research showing that extending the length of CPT by adding more sessions can improve overall rates of recovery.19,20 In an earlier clinical trial of weekly CPT, for instance, 38.7% of active-duty military personnel who completed CPT scheduled twice weekly achieved good end-state by the twelfth and final session and another 20% reached good end-state following additional CPT sessions.19 Critically, 41.3% of CPT completers did not reach good end-state despite receiving 24 sessions of CPT (double CPT's typical "dose"), lending some support for the second possibility: CPT induces change in some, but not enough, causal factors. For this latter subgroup of patients, switching to a different trauma therapy that targets different causal factors may be indicated. Treatment switching is a common strategy in routine clinical practice when patients do not respond to an initial first line treatment. To our knowledge, the effectiveness of switching from one trauma therapy to another has never been investigated. As a result, there are currently no evidence-based decision rules to guide clinician and patient choice regarding "next steps" when patients do not benefit from CPT or any other trauma-focused therapy. This study will therefore be the first to investigate a critical question commonly asked by clinicians and patients: if a patient has not fully recovered from PTSD by the end of a first-line treatment like CPT, should the clinician continue CPT or should they instead switch to a different treatment modality? PTSD is often examined through a psychological lens, however due to the complex relationship between emotional and cognitive processes, there is an increased interest in examining the unique role that cognitive impairment plays in the development and maintenance of PTSD symptoms.22 Due to the frequency of poor PTSD treatment response, active military personnel frequently experience lingering cognitive impairments that may be due to PTSD. These cognitive impairments in turn often hinder recovery from PTSD by negatively affecting treatment response. The most robust findings suggest cognitive impairments in the domains of learning, executive functioning, processing speed, attention, and working memory in individuals with PTSD.4,5 Previous research suggests that cognitive impairments in individuals with PTSD can improve4, however data is limited, especially in active-duty military personnel.
Treatments that provide rapid and sustained reduction from psychological symptoms and cognitive impairments are direly needed, especially in specialized military populations and in "real-world" military settings. Pilot data collected by our team indicate that, as compared to usual care PTSD treatment, massed CPT treatment accelerates reductions in PTSD symptoms among military personnel and veterans. Other previous research suggests adaptive designs utilizing variable-length treatments may also improve treatment efficacy.19 This study will build on these promising findings by utilizing an innovative two-stage clinical trial design evaluating variable-length massed (i.e. daily) PTSD treatment administered under routine operational conditions. Military personnel who do not respond adequately to massed CPT treatment will be randomized to receive additional CPT or EMDR sessions. This design allows us to causally examine the efficacy of increasing treatment dose versus cross-treatment factors that target a broader range of mechanisms.
- Conditions
- PTSD, Cognitive Performance
- Being tested
- Cognitive Processing Therapy, Eye-Movement Desensitization and Reprocessing
- Keywords
- PTSD, CPT, Military
- Medical subject headings
- Stress Disorders, Post-Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Processing TherapyBehavioural
Also called CPT
CPT is an empirically supported psychotherapy for PTSD that focuses on why patients believe the traumatic event occurred, how that event affected their beliefs about self and others, and how to evaluate their beliefs. Patients learn to label events, thoughts, and subsequent emotions while the therapist helps them examine the facts Session Focus and context of the trauma through Socratic questioning. Using progressive worksheets, patients are taught to examine their own thoughts and emotions and develop new, more balanced thinking about traumatic events. CPT's safety and efficacy is well-established; over 80% of patients receiving the treatment benefit and > 50% reductions in PTSD symptoms are typical.
Eye-Movement Desensitization and ReprocessingBehavioural
Also called EMDR
EMDR is another empirically supported trauma-focused psychotherapy that is strongly recommended for the treatment of PTSD by the VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder (VA/DOD, 2023). Results of multiple clinical trials indicate EMDR's effectiveness for reducing PTSD symptoms is comparable to CPT's. EMDR directs patients to think about different aspects of an emotionally upsetting memory in mind while simultaneously focusing on an external stimulus. The most common external stimulus is therapist-directed lateral eye movements (e.g., tracking the movement of a therapist's finger back and forth with only the eyes) but other stimuli (e.g., hand-tapping, audio stimulation) can also be used. Half of participants who do not reach good end-state by session 10 will be randomly assigned to receive up to 5 sessions of EMDR during Stage 2.
| Study group | Role | What they receive |
|---|---|---|
| 10 Sessions | Experimental | If participants reach good end-state functioning by the end of massed CPT (i.e., session 10), treatment will be discontinued. Receives: Behavioral: Cognitive Processing Therapy |
| Additional Sessions | Experimental | If participants do not reach good end-state functioning, they will proceed to Stage 2. In the second stage of treatment, participants will receive up to five additional therapy sessions. Participants will be randomized to receive either 5 more sessions of CPT, or 5 sessions of EMDR. Receives: Behavioral: Cognitive Processing Therapy; Behavioral: Eye-Movement Desensitization and Reprocessing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Good End-State Functioning
Good end-state is defined as (a) a score on the PCL-5 ≤ 19 and (b) mutual agreement by the patient and therapist that the patient has achieved the therapy's goals. The PCL-5 is a validated self-report scale that assesses the severity of DSM-5-defined PTSD symptoms within the past week. 28 Items are summed so that higher scores reflect greater symptom severity. Previous research shows that over 94% of military personnel with good end-state following trauma-focused therapy had clinically meaningful improvement in PTSD symptoms using the Reliable Change Index and 79-100% no longer meet DSM-5 criteria for a diagnosis of PTSD.
Measured: From enrollment to the end of study participation 12 months after enrollment
Secondary outcomes (12)
PTSD Symptom Severity
feedback system during treatment.
Measured: From Enrollment to end of study participation 12 months after enrollment
Cognitive Performance
Cognitive performance will be assessed using the DANA,24 a self-administered mobile phone-based application designed to rapidly assess multiple dimensions of neurocognitive performance in as little as 15 minutes. The DANA was selected as our secondary outcome measure because it has been validated as a tool for diagnosing traumatic brain injury (TBI) among military personnel, can be self-administered by participants on their smart phones, and will be soon used by JSOC cognitive professionals.
Measured: From Enrollment to the end of study participation 12 months after enrollment
Demographics
A standardized demographics form will assess demographic variables including sex, gender, age, and race.
Measured: Single time point at enrollment
military service demographics
A military service demographics form based on the Million Veterans Program survey will be used to assess military-specific variables (e.g., rank, Service Branch).
Measured: A single time point at enrollment
Trauma exposure
Trauma exposure will be assessed using the Life Events Checklist for DSM-5.
Measured: A single time point at enrollment
TBI
History of TBI will be assessed using The Ohio State University Traumatic Brain Injury Identification Method.
Measured: A single time point at enrollment
Alcohol use
Alcohol-related problems will be assessed using the Alcohol Use Disorders Identification Test.
Measured: From enrollment to the end of study participation 12 months after enrollment
Sleep Quality
Sleep quality will be assessed using the Insomnia Severity Index (ISI).
Measured: From enrollment to the end of study participation 12 months after enrollment.
Depression symptoms
Depression symptoms will be assessed using the Patient Health Questionnaire.
Measured: From enrollment to the end of study participation 12 months following enrollment
Suicide risk
Suicide risk will be measured with the Brief Suicide Cognitions Scale.
Measured: From enrollment to the end of study participation 12 months following enrollment
Trauma-related beliefs
Trauma-related beliefs will be assessed using the shortened version of the Posttraumatic Cognitions Inventory.
Measured: From enrollment to the end of study participation 12 months following enrollment
Treatment satisfaction
Treatment satisfaction will be assessed using the Satisfaction with Therapy and Therapist Scale- Revised
Measured: One time point 1 month after finishing treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2026
- Study start1 Apr 2026
- Primary completionAug 2028 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PTSDStudies of the same condition, open and under way.
- More trials run by Ohio State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- This study will be utilizing a two-stage clinical trial design evaluating variable-length massed (i.e. daily) PTSD treatment administered under routine operational conditions. Military personnel who do not respond adequately to massed CPT treatment will be randomized to receive additional CPT or EMDR sessions. This design allows us to causally examine the efficacy of increasing treatment dose versus cross-treatment factors that target a broader range of mechanisms.
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ohio State University
- Sponsor type
- University, hospital or other
- Collaborators
- Congressionally Directed Medical Research Programs
- Responsible party
- Principal investigator, Jaryd Hiser, Ohio State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07680517
- Sponsor's protocol ID
- HT9425-25-1-0944
- Other IDs
- HT9425-25-1-0944
- Status last verified
- Jun 2026
- First submitted
- 22 Jun 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data available by request
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms
- ClinicalTrials.gov ID
- NCT07680517
- Acronym / sponsor ID
- HT9425-25-1-0944
- Conditions
- PTSD, Cognitive Performance
- Keywords
- PTSD, CPT, Military
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Ohio State UniversityUniversity, hospital or other
- Collaborators
- Congressionally Directed Medical Research Programs
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- Aug 2028 (estimated)
- Study completion
- Aug 2028 (estimated)
- First posted
- 2 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT and EMDR) in "real-world" military settings. CPT and EMDR are both empirically supported psychotherapies for PTSD. To accomplish this objective, we will enroll military personnel meeting diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting threshold levels for 3 of 4 symptom criteria).
Detailed description
Posttraumatic stress disorder (PTSD) is considered one of the "signature injuries" of military operations and is the most frequently diagnosed mental health condition among active-duty military personnel. PTSD is associated with a host of psychological problems (i.e., intrusions, avoidance, negative alterations in cognition/mood, and hyperarousal) and negative outcomes (i.e., occupational and marital dissatisfaction, violence, alcohol and substance abuse, and suicide).1-3 PTSD has also been correlated with poorer cognitive performance across various domains including attention, working memory, processing speed, and executive functioning.4,5 These psychological problems and cognitive impairments significantly impact military personnel's deployment readiness and overall quality of life.
Numerous randomized clinical trials support the efficacy of trauma-focused treatments like cognitive processing therapy (CPT) with multiple populations including active-duty military personnel.6-8 For this reason, CPT is one of three individual manualized trauma-focused psychotherapies that is strongly recommended for the treatment of PTSD by the VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder.9 Recent advances in PTSD treatment have shown that the effects of CPT on PTSD symptom reduction and remission are retained when the treatment is delivered in a "massed" format, which entails daily therapy sessions during a 2-3 week window instead of the traditional schedule of one session per week for multiple months.16,23 Massed CPT therefore achieves similar reductions in PTSD symptoms within a much shorter timeframe. Our team has shown, for instance, that over 70% of military personnel and veterans who received CPT in this format no longer met criteria for a PTSD diagnosis at treatment end.10,11 As compared to conventional therapy delivered weekly, massed trauma therapy has higher treatment retention and treatment completion.12 Massed models are also believed to reduce distraction, avoidance, and de-motivation that typically occurs between weekly sessions.13 Meeting with a therapist daily may also increase commitment to therapy due to a greater sense of support.14 Therefore, this strategy would allow increased access to therapy due to higher patient throughput, while providing patients with rapid and sustained symptom reduction, through improved treatment engagement and improved long-term outcomes.
Despite massed CPT's considerable promise, the effectiveness of this delivery model in real-world military settings remains poorly understood because previous research has only been conducted in highly controlled settings using specially trained research therapists who are closely monitored for protocol fidelity and reduced caseloads. The effectiveness of massed CPT when implemented in real-world military settings when delivered by military behavioral health professionals working in busy clinics with high caseloads, multiple competing work demands, and limited time to pursue case consultation and clinical supervision remains unknown, limiting our understanding of how previous research findings will translate to practice settings within a busy military operational environment. These possible barriers to effective implementation are magnified in Special Operations Forces (SOF) units, which typically have a greater number of deployments and often experience more intense combat than conventional forces-two factors associated with higher prevalence of PTSD.15,16 This is especially true for active-duty military personnel, who show attenuated treatment response as compared to civilians.17,18 Recent research has suggested that over 50% of service members retain their PTSD diagnosis after completing weekly CPT.7 PTSD symptom persistence may be explained by insufficient engagement of key causal factors: first, CPT may not induce enough change in relevant causal factors for recovery to occur, implicating the need for higher "doses" of therapy; second, CPT may induce change in only some, but not enough, causal factors, implicating the need for multiple (or different) treatments that target a broader range of causal factors. Supporting the first possibility is research showing that extending the length of CPT by adding more sessions can improve overall rates of recovery.19,20 In an earlier clinical trial of weekly CPT, for instance, 38.7% of active-duty military personnel who completed CPT scheduled twice weekly achieved good end-state by the twelfth and final session and another 20% reached good end-state following additional CPT sessions.19 Critically, 41.3% of CPT completers did not reach good end-state despite receiving 24 sessions of CPT (double CPT's typical "dose"), lending some support for the second possibility: CPT induces change in some, but not enough, causal factors. For this latter subgroup of patients, switching to a different trauma therapy that targets different causal factors may be indicated. Treatment switching is a common strategy in routine clinical practice when patients do not respond to an initial first line treatment. To our knowledge, the effectiveness of switching from one trauma therapy to another has never been investigated. As a result, there are currently no evidence-based decision rules to guide clinician and patient choice regarding "next steps" when patients do not benefit from CPT or any other trauma-focused therapy. This study will therefore be the first to investigate a critical question commonly asked by clinicians and patients: if a patient has not fully recovered from PTSD by the end of a first-line treatment like CPT, should the clinician continue CPT or should they instead switch to a different treatment modality? PTSD is often examined through a psychological lens, however due to the complex relationship between emotional and cognitive processes, there is an increased interest in examining the unique role that cognitive impairment plays in the development and maintenance of PTSD symptoms.22 Due to the frequency of poor PTSD treatment response, active military personnel frequently experience lingering cognitive impairments that may be due to PTSD. These cognitive impairments in turn often hinder recovery from PTSD by negatively affecting treatment response. The most robust findings suggest cognitive impairments in the domains of learning, executive functioning, processing speed, attention, and working memory in individuals with PTSD.4,5 Previous research suggests that cognitive impairments in individuals with PTSD can improve4, however data is limited, especially in active-duty military personnel.
Treatments that provide rapid and sustained reduction from psychological symptoms and cognitive impairments are direly needed, especially in specialized military populations and in "real-world" military settings. Pilot data collected by our team indicate that, as compared to usual care PTSD treatment, massed CPT treatment accelerates reductions in PTSD symptoms among military personnel and veterans. Other previous research suggests adaptive designs utilizing variable-length treatments may also improve treatment efficacy.19 This study will build on these promising findings by utilizing an innovative two-stage clinical trial design evaluating variable-length massed (i.e. daily) PTSD treatment administered under routine operational conditions. Military personnel who do not respond adequately to massed CPT treatment will be randomized to receive additional CPT or EMDR sessions. This design allows us to causally examine the efficacy of increasing treatment dose versus cross-treatment factors that target a broader range of mechanisms.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study will be utilizing a two-stage clinical trial design evaluating variable-length massed (i.e. daily) PTSD treatment administered under routine operational conditions. Military personnel who do not respond adequately to massed CPT treatment will be randomized to receive additional CPT or EMDR sessions. This design allows us to causally examine the efficacy of increasing treatment dose versus cross-treatment factors that target a broader range of mechanisms.
| Arm | Type | Receives |
|---|---|---|
| 10 Sessions | Experimental | Behavioral: Cognitive Processing TherapyIf participants reach good end-state functioning by the end of massed CPT (i.e., session 10), treatment will be discontinued. |
| Additional Sessions | Experimental | Behavioral: Cognitive Processing Therapy, Behavioral: Eye-Movement Desensitization and ReprocessingIf participants do not reach good end-state functioning, they will proceed to Stage 2. In the second stage of treatment, participants will receive up to five additional therapy sessions. Participants will be randomized to receive either 5 more sessions of CPT, or 5 sessions of EMDR. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- -Treatment-seeking military personnel (i.e., any assigned or aligned JSOC personnel) who meet diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting diagnostic threshold for 3 of 4 symptom criteria who are (1) 18 years of age or older; (2) current diagnosis of PTSD or subthreshold PTSD (i.e. meeting diagnostic criteria for 3 of 4 symptom criteria, assessed using the DIAMOND); (3) current military personnel; (4) ability to speak and understand the English language; and (5) ability to complete the informed consent process
Key exclusion criteria (1 listed)
- (1) substance use disorder requiring medical management; (2) imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and (3) impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Processing TherapyAlso: CPTCPT is an empirically supported psychotherapy for PTSD that focuses on why patients believe the traumatic event occurred, how that event affected their beliefs about self and others, and how to evaluate their beliefs. Patients learn to label events, thoughts, and subsequent emotions while the therapist helps them examine the facts Session Focus and context of the trauma through Socratic questioning. Using progressive worksheets, patients are taught to examine their own thoughts and emotions and develop new, more balanced thinking about traumatic events. CPT's safety and efficacy is well-established; over 80% of patients receiving the treatment benefit and > 50% reductions in PTSD symptoms are typical. | Behavioural | 10 Sessions, Additional Sessions |
| Eye-Movement Desensitization and ReprocessingAlso: EMDREMDR is another empirically supported trauma-focused psychotherapy that is strongly recommended for the treatment of PTSD by the VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder (VA/DOD, 2023). Results of multiple clinical trials indicate EMDR's effectiveness for reducing PTSD symptoms is comparable to CPT's. EMDR directs patients to think about different aspects of an emotionally upsetting memory in mind while simultaneously focusing on an external stimulus. The most common external stimulus is therapist-directed lateral eye movements (e.g., tracking the movement of a therapist's finger back and forth with only the eyes) but other stimuli (e.g., hand-tapping, audio stimulation) can also be used. Half of participants who do not reach good end-state by session 10 will be randomly assigned to receive up to 5 sessions of EMDR during Stage 2. | Behavioural | Additional Sessions |
Primary outcome
Good End-State Functioning
Time frame: From enrollment to the end of study participation 12 months after enrollment
Good end-state is defined as (a) a score on the PCL-5 ≤ 19 and (b) mutual agreement by the patient and therapist that the patient has achieved the therapy's goals. The PCL-5 is a validated self-report scale that assesses the severity of DSM-5-defined PTSD symptoms within the past week. 28 Items are summed so that higher scores reflect greater symptom severity. Previous research shows that over 94% of military personnel with good end-state following trauma-focused therapy had clinically meaningful improvement in PTSD symptoms using the Reliable Change Index and 79-100% no longer meet DSM-5 criteria for a diagnosis of PTSD.
12 secondary outcomes
PTSD Symptom Severity
Time frame: From Enrollment to end of study participation 12 months after enrollment
Cognitive Performance
Time frame: From Enrollment to the end of study participation 12 months after enrollment
Demographics
Time frame: Single time point at enrollment
military service demographics
Time frame: A single time point at enrollment
Trauma exposure
Time frame: A single time point at enrollment
TBI
Time frame: A single time point at enrollment
Alcohol use
Time frame: From enrollment to the end of study participation 12 months after enrollment
Sleep Quality
Time frame: From enrollment to the end of study participation 12 months after enrollment.
Depression symptoms
Time frame: From enrollment to the end of study participation 12 months following enrollment
Suicide risk
Time frame: From enrollment to the end of study participation 12 months following enrollment
Trauma-related beliefs
Time frame: From enrollment to the end of study participation 12 months following enrollment
Treatment satisfaction
Time frame: One time point 1 month after finishing treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data available by request
Related trials for PTSD
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Not yet recruitingPhase 3
Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Post-Traumatic Stress Disorder, PTSD
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Recruiting
Advancing Skills Through Consultation, Education, and Novel Technologies
PTSD - Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Processing Therapy and Eye-Movement Desensitization and Reprocessing in people with PTSD and Cognitive Performance, run by Ohio State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jaryd Hiser, PhD (6146858746, Jaryd.Hiser@osumc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Good End-State Functioning (time frame: From enrollment to the end of study participation 12 months after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.